In a study that evaluated glomerulopathies during COVID-19, MCD was present in one case of 17 patients (14); this was the first case described in the literature of MCD associated with HRG-APOL-1 in a COVID-19 patient and revealed the presence of “interferon footprints,” demonstrating the importance of the role of cytokine-mediated podocyte injury in predisposed individuals. The gene discussed is APOL1; the disease is COVID-19.